US 11407723
Selective histone deacetylase inhibitors for the treatment of human disease
granted A61KA61K31/165A61K31/433
Quick answer
US patent 11407723 (Selective histone deacetylase inhibitors for the treatment of human disease) held by Shuttle Pharmaceuticals, Inc. expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Shuttle Pharmaceuticals, Inc.
- Grant date
- Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K31/165, A61K31/433, A61K45/06, A61P